Five things for pharma marketers to know: Thursday, October 5, 2017

Share this content:

1. Cigna will no longer cover Purdue Pharma's OxyContin, starting in 2018. Instead, it will cover Collegium Pharmaceutical's Xtampza ER, an abuse-deterrent painkiller. (Reuters)

2. The American Medical Association no longer supports government regulation of drug prices. Their concern? That they wouldn't be able to defend against arguments for price-fixing for physicians. (Axios)  

3. FDA commissioner Scott Gottlieb told lawmakers he does not favor a federal “right-to-try” law, which would allow terminally ill patients to take unapproved medications if they want to. (MedPage Today)

4. Alnylam has spent more than $1 billion to develop its experimental RNAi therapy and is in position to be the first company to receive FDA approval for this kind of drug. (Stat)

5. Drugmakers are worried about national shortages of drugs manufactured in Puerto Rico. Drugs and devices are Puerto Rico's top exports. (NYT)

Share this content:
Scroll down to see the next article